PB vs Industry: VRTX is overvalued based on its PB Ratio (6.8x) compared to the US Biotechs industry average (2x).
Similarly Why did VRTX stock drop? Vertex Pharma (NASDAQ:VRTX) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. That trial was testing the effectiveness of VX-864. This is a possible treatment for patients suffering from alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
Is Vertex Pharmaceuticals a monopoly? As a functioning monopoly, VRTX can invest its free cash flows into research and development. Due to this, the company has built an enticing drug pipeline.
Additionally, Why did Vertex drop in October?
Shares of Vertex Pharmaceuticals ( VRTX 1.61% ) fell 23.4% in October, according to data from S&P Global Market Intelligence after the biotech discontinued development of a drug for alpha-1 antitrypsin deficiency (AATD).
What kind of company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts.
…
Vertex Pharmaceuticals.
| Type | Public company |
|---|---|
| Industry | Pharmaceuticals & Biotherapeutics |
| Founded | 1989 |
| Headquarters | Boston, Massachusetts, U.S. |
Who bought Vertex? Vertex is majority owned by American Industrial Partners Capital Fund VI LP (AIP), a fund managed by an operationally oriented private equity firm with $8 billion of assets under management (for more information on AIP visit americanindustrial.com).
What drugs does vertex make? Our Approved Medicines
- KALYDECO® (ivacaftor) Medicine Name. …
- ORKAMBI® (lumacaftor/ivacaftor) …
- SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) …
- SYMKEVI® (tezacaftor/ivacaftor) + KALYDECO® (ivacaftor) …
- TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) …
- KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) + KALYDECO® (ivacaftor)
What drugs does Vertex Pharmaceuticals make? Our Approved Medicines
- KALYDECO® (ivacaftor) Medicine Name. …
- ORKAMBI® (lumacaftor/ivacaftor) …
- SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) …
- SYMKEVI® (tezacaftor/ivacaftor) + KALYDECO® (ivacaftor) …
- TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) …
- KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) + KALYDECO® (ivacaftor)
What are Vertex drugs?
Vertex’s second cystic fibrosis drug, Orkambi, was approved in 2015. That was followed by Symdeko in 2018. Both products were two-drug combinations (backboned by Kalydeco), which dramatically expanded the number of cystic fibrosis cases that could be treated. But Orkambi and Symdeko were also less effective.
What happened to Vertex Pharmaceuticals in October? [Updated: 4/13/2021] VRTX Stock Undervalued
Firstly, in mid-October 2020, the company discontinued VX-814, a drug that was being investigated for a potential treatment for alpha-1 antitrypsin deficiency. This development caused a large 20% hit to the stock in a single trading session.
Is Vertex a Fortune 500?
RANK448. The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year revenue increase in 2020—driven primarily by its cystic fibrosis drugs Kaftrio and Trikafta.
What is Vertex Pharmaceuticals known for? Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
What kind of company is vertex?
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
Is Vertex publicly traded?
The Company went public in 1991. What exchange is Vertex stock listed on? What is Vertex’s stock symbol? Vertex is listed on The Nasdaq National Market under the ticker symbol VRTX.
Where is vertex based? Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts .
…
Vertex Pharmaceuticals.
| Type | Public company |
|---|---|
| Industry | Pharmaceuticals & Biotherapeutics |
| Founded | 1989 |
| Headquarters | Boston, Massachusetts, U.S. |
How effective is Kalydeco? In the U.S. cohort, patients taking Kalydeco had a decrease in FEV of 0.7%, whereas the reduction for those not taking the treatment was 8.3%. In the U.K. cohort, the therapy improved pulmonary function (increase of 4.9% in FEV values), compared to FEV decrease of 4.3% in patients not receiving Kalydeco.
Is Vertex a good company to work for?
90% of employees at Vertex Pharmaceuticals Inc say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.
Is Vertex Pharmaceuticals a US company? Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts.
…
Vertex Pharmaceuticals.
| Type | Public company |
|---|---|
| Revenue | US$3.04 billion (2018) |
| Number of employees | 3,900 |
| Website | vrtx.com |
Is vertex a good company to work for?
90% of employees at Vertex Pharmaceuticals Inc say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.
Who bought vertex? Vertex is majority owned by American Industrial Partners Capital Fund VI LP (AIP), a fund managed by an operationally oriented private equity firm with $8 billion of assets under management (for more information on AIP visit americanindustrial.com).
